Axsome Therapeutics
Price & Volume
Stats
See more52W Range | $96.09-$217 |
Market Cap | $9.4B |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $638.4M |
Revenue Growth (YoY) | 65% |
Gross Profit (12 Mos) | $591M |
Diluted EPS | -$3.68 |
News
See moreYahoo Finance • 13 hours ago
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
Yahoo Finance • 18 days ago
Is Axsome Therapeutics (AXSM) Still Attractively Priced After Its 72% One-Year Surge
Yahoo Finance • 19 days ago
Axsome Faces Key Auvelity FDA Call And Insider Sentiment Test
Yahoo Finance • 21 days ago
Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says
About
CEO | Dr. Herriot Tabuteau M.D. |
Address | One World Trade Center, New York, NY, United States, 10007 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 925 |